Xurodopa 275 Tablet containing Levodopa and Carbidopa is used for the management of Parkinson's disease and related movement disorders. It helps improve motor function, reduce movement-related symptoms, and enhance quality of life.
Levodopa serves as a precursor to dopamine and helps replenish dopamine levels in the brain, while Carbidopa inhibits the peripheral breakdown of Levodopa, allowing more of the medicine to reach the brain and provide effective symptom control.
The tablet is widely prescribed in neurology practice for managing Parkinsonian symptoms such as tremors, rigidity, bradykinesia, and postural instability, leading to consistent prescription demand.
With increasing prevalence of neurological disorders and growing demand for effective Parkinson's disease management therapies, this product offers strong business potential for retailers and distributors. Its established therapeutic value, broad clinical relevance, and steady market demand make it a reliable product for growth in the neurocare segment.